Sunesis Pharmaceuticals, an emerging pharmaceutical company, agreed to acquire Viracta Therapeutics, a privately held precision oncology company targeting virus-associated malignancies. Financial terms were not disclosed. "After a thorough evaluation of strategic alternatives, the Board of Directors of Sunesis believes this merger is in the best interest of Sunesis’ stockholders and has the potential to deliver near- and long-term value. This transaction will provide the resources for the combined company to leverage Viracta’s scientific platform and pipeline to treat a range of virus-associated cancers and other serious diseases. Viracta shares our mission to develop important new targeted treatments for patients living with cancer, and we are enthusiastic about the prospect of carrying on that mission," Dayton Misfeldt, Sunesis CEO.